Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMYDA-10 semaglutide OCT trial in diabetic patients with acute coronary syndrome
2025-523977-40-00Phase 4Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoint: Change in maximum macrophage arc. Planned start Jan 2026; status: authorised.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2025-523977-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523977-40-00.